|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Abbott |
| Information provided by: | Abbott |
| ClinicalTrials.gov Identifier: | NCT00073710 |
Purpose
A study to investigate the effects of Zemplar and Calcijex on intestinal calcium absorption in hemodialysis subjects.
| Condition | Intervention | Phase |
|
Secondary Hyperparathyroidism Chronic Kidney Disease |
Drug: Zemplar Procedure: 42 Ca carbonate absorption via single tracer method Drug: Calcijex |
Phase IV |
| Drug Information available for: | Calcium gluconate Calcitriol 19-Nor-1alpha,25-dihydroxyvitamin D2 |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Safety/Efficacy Study |
| Official Title: | A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium |
Eligibility
| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:
Exclusion Criteria
Contacts and Locations
More Information
| Study ID Numbers: | M01-375 |
| First Received: | December 3, 2003 |
| Last Updated: | July 31, 2006 |
| ClinicalTrials.gov Identifier: | NCT00073710 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|